INBRX-106 Clinical Trials (2026): 3 Studies for Gastric Cancer & Head and Neck Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 INBRX-106 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Gastric Cancer & Head and Neck Cancer) and 762 total planned enrollment. 2 INBRX-106 clinical trials are actively recruiting at 16 U.S. sites across 8 states. Most recent activity: NCT04198766 (Jul 2033).
Where to Participate: All INBRX-106 Trial Sites in the U.S. (16 sites across 8 states)
Every actively recruiting INBRX-106trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope | Duarte91010 | NCT04198766 | Map |
| CA | Los Angeles Cancer Network | Glendale91204 | NCT04198766 | Map |
| CA | California Research Institute | Los Angeles90027 | NCT04198766 | Map |
| CA | Ellison Institute of Technology (EITM) | Los Angeles90064 | NCT06353997 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90069 | NCT04198766 | Map |
| CA | Valkyrie Clinical Trials | Murrieta92562 | NCT04198766 | Map |
| CA | Providence Medical Foundation | Santa Rosa95403 | NCT04198766 | Map |
| FL | Clermont Oncology Center | Clermont34711 | NCT04198766 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT04198766 | Map |
| GA | Winship Cancer Institute - Emory University | Atlanta30322 | NCT04198766 | Map |
| KY | Norton Cancer Institute | Louisville40202 | NCT04198766 | Map |
| MI | Henry Ford Cancer Institute | Detroit48202 | NCT04198766 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT04198766 | Map |
| OR | Providence Portland Cancer Institute - Franz Clinic | Portland97213 | NCT06353997 | Map |
| OR | Providence St. Vincent Medical Center | Portland97225 | NCT06353997 | Map |
| TX | The University of Texas Health Science Center at Tyler | Tyler75701 | NCT04198766 | Map |
INBRX-106 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1/P2 | 1 | 1 | |
| P2 | 1 | 1 | |
| P2/P3 | 1 | 1 |
Recruiting INBRX-106 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | P1/P2 | Solid Tumor | 340 | Dec 2019 |
| NCT06353997 | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | P2 | Triple Negative Breast Cancer | 12 | Sep 2024 |
INBRX-106 clinical trials by indication
Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06353997 | — | P2 | recruiting | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients |
Head and Neck Squamous Cell Carcinoma (HNSCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06295731 | HexAgon-HN | P2/P3 | active not recruiting | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC |
Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04198766 | — | P1/P2 | recruiting | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) |
All INBRX-106 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | P1/P2 | recruiting | 340 | Inhibrx Biosciences, Inc | Dec 2019 | |
| NCT06353997 | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | P2 | recruiting | 12 | Providence Health & Services | Sep 2024 | |
| NCT06295731 | HexAgon-HN | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | P2/P3 | active not recruiting | 410 | Inhibrx Biosciences, Inc | May 2024 |
INBRX-106 clinical trials: frequently asked questions
- How many INBRX-106 clinical trials are there?
- 3 INBRX-106 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are INBRX-106 clinical trials recruiting in 2026?
- Yes — 2 INBRX-106 trials are actively recruiting in 2026, with 16 U.S. sites across 8 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is INBRX-106 being studied for?
- INBRX-106 is being studied for Gastric Cancer, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, Non-Small Cell Lung Cancer and 4 more. The trials are grouped by indication on this page.
- What phase is INBRX-106 in?
- INBRX-106 clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors INBRX-106 clinical trials?
- The lead sponsor across the most INBRX-106 trials is Inhibrx Biosciences, Inc, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming INBRX-106as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: